You searched for Bengt Jonsson - OHE

We found for

Optimise_AdobeStock_576507456_landscape

Insight
April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1

Insight
December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Sustainability

Supporting the Era of Green Pharmaceuticals in the UK

Read more

Gene therapy DNA 3D chemical molecule structure low poly. Polygonal triangle point line healthy cell part. Innovation medicine genome engineering vector illustration future business technology

Insight
June 2022

ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?

Rare-Disease-Day-tiny

Insight
February 2022

Rare Disease Day 2022

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Read more

© NCI/Unsplash

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Read more

© WellcomeCollection

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Read more

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

Read more

Insight
December 2020

A NICE Wind of Change? The What and So What of the NICE Methods Consultation

News
January 2020

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

Read more

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions

Read more

Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?

Read more